Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T14:25:34.376Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive–compulsive disorder

Published online by Cambridge University Press:  27 July 2021

Ghina Harika-Germaneau Open the ORCID record for Ghina Harika-Germaneau [Opens in a new window] ,
Nicolas Langbour ,
Sylvie Patri ,
Marcello Solinas ,
Armand Chatard ,
Bruno Millet ,
Farshad Hashemian ,
Marie-Christine Pérault-Pochat ,
Nematollah Jaafari  and
Claire Lafay-Chebassier Open the ORCID record for Claire Lafay-Chebassier [Opens in a new window]
Ghina Harika-Germaneau
Affiliation:
Unité de Recherche Clinique Intersectorielle en Psychiatrie, Centre Hospitalier Henri Laborit, Poitiers, France INSERM U1084 - Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France
Nicolas Langbour
Affiliation:
Unité de Recherche Clinique Intersectorielle en Psychiatrie, Centre Hospitalier Henri Laborit, Poitiers, France
Sylvie Patri
Affiliation:
Département de Génétique, CHU de Poitiers, Poitiers, France
Marcello Solinas
Affiliation:
Unité de Recherche Clinique Intersectorielle en Psychiatrie, Centre Hospitalier Henri Laborit, Poitiers, France INSERM U1084 - Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France
Armand Chatard
Affiliation:
Unité de Recherche Clinique Intersectorielle en Psychiatrie, Centre Hospitalier Henri Laborit, Poitiers, France Département de Psychologie - CNRS 7295, Université de Poitiers, Poitiers, France
Bruno Millet
Affiliation:
AP-HP, Service de Psychiatrie Adulte de la Pitié-Salpêtrière, Institut du Cerveau, ICM, Sorbonne Université, Paris, France
Farshad Hashemian
Affiliation:
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Marie-Christine Pérault-Pochat
Affiliation:
INSERM U1084 - Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France Service de Pharmacologie Clinique et Vigilances, CHU de Poitiers, Poitiers, France Centre d’Investigation Clinique - INSERM CIC 1402, CHU de Poitiers, Poitiers, France
Nematollah Jaafari
Affiliation:
Unité de Recherche Clinique Intersectorielle en Psychiatrie, Centre Hospitalier Henri Laborit, Poitiers, France INSERM U1084 - Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France
Claire Lafay-Chebassier*
Affiliation:
INSERM U1084 - Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France Service de Pharmacologie Clinique et Vigilances, CHU de Poitiers, Poitiers, France Centre d’Investigation Clinique - INSERM CIC 1402, CHU de Poitiers, Poitiers, France
*
*Author for correspondence: Claire Lafay-Chebassier, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Obsessive–compulsive disorder (OCD) is a severe psychiatric disorder characterized by its heterogeneous nature and by different dimensions of obsessive–compulsive (OC) symptoms. Serotonin reuptake inhibitors (SRIs) are used to treat OCD, but up to 40% to 60% of patients do not show a significant improvement with these medications. In this study, we aimed to test the impact of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on the efficacy of antidepressants in OCD overall, and in relation to the different OC dimensions.

Methods

In a 6-month prospective treatment study, 69 Caucasian OCD patients were treated with escitalopram for 24 weeks or with escitalopram for 12 weeks followed by paroxetine for an additional 12-week period. Patients were genotyped and assessed for treatment response. The main clinical outcomes were improvement of the Yale-Brown Obsessive–Compulsive Scale score and in different OC symptom dimension scores.

Results

The Val/Val group comprised 43 (62%) patients, the Val/Met and Met/Met group comprised 26 (38%) patients. Forty-two patients were classified as responders at 12 weeks and 38 at 24 weeks; no significant association was found between BDNF Val66Met and SRIs response at 12 and 24 weeks. In analyses of the different OC symptom dimensions, the Met allele was associated with a slightly reduced score in the aggressive/checking dimension at 6 months (P = .048).

Conclusions

Our findings do not support the usefulness of BDNF Val66Met genotyping to predict overall response to treatment with SRIs in OCD; they did however suggest a better outcome at 6 months for the aggressive/checking symptom dimension for patients carrying the Met allele.

Keywords

BDNF Val66Met polymorphismobsessive–compulsive disorderOC symptom dimensionsantidepressantsresponse
Type
Original Research
Information
CNS Spectrums , Volume 27 , Issue 5 , October 2022 , pp. 645 - 651
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ruscio, AM, Stein, DJ, Chiu, WT, et al. The epidemiology of obsessive–compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53–63.CrossRefGoogle ScholarPubMed
Landeros-Weisenberger, A, Bloch, MH, Kelmendi, B, et al. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. J Affect Disord. 2010;121(1–2):175–179.CrossRefGoogle ScholarPubMed
Mataix-Cols, D, Rosario-Campos, MC, Leckman, JF. A multidimensional model of obsessive–compulsive disorder. Am J Psychiatry. 2005;162(2):228–238.CrossRefGoogle ScholarPubMed
Wang, S, Xu, X, Yan, P, et al. Is brain-derived neurotrophic factor (BDNF) Val66Met polymorphism associated with obsessive–compulsive disorder? A meta-analysis. Psychiatr Danub. 2019;31(2):141–147.CrossRefGoogle ScholarPubMed
Park, H, Poo, M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013;14(1):7–23.CrossRefGoogle ScholarPubMed
Egan, MF, Kojima, M, Callicott, JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257–269.CrossRefGoogle ScholarPubMed
Chen, ZY, Patel, PD, Sant, G, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004;24(18):4401–4411.CrossRefGoogle ScholarPubMed
Umehara, H, Numata, S, Kinoshita, M, et al. No association between BDNF Val66Met polymorphism and treatment response in obsessive–compulsive disorder in the Japanese population. Neuropsychiatr Dis Treat. 2016;12:611–615.Google ScholarPubMed
Taj, MJRJ, Ganesh, S, Shukla, T, et al. BDNF gene and obsessive compulsive disorder risk, symptom dimensions and treatment response. Asian J Psychiatr. 2018;38:65–69.CrossRefGoogle Scholar
Abdolhosseinzadeh, S, Alizadeh, N, Shams, J, et al. BDNF association study with obsessive–compulsive disorder, its clinical characteristics, and response to fluvoxamine-treatment in Iranian patients. Exp Clin Psychopharmacol. 2020;28(2):216–224.CrossRefGoogle ScholarPubMed
Real, E, Gratacòs, M, Soria, V, et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive–compulsive disorder. Biol Psychiatry. 2009;66(7):674–680.CrossRefGoogle ScholarPubMed
Anderson, IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7(suppl 1):11–17.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18(4):289–299.CrossRefGoogle Scholar
Matrisciano, F, Bonaccorso, S, Ricciardi, A, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res. 2009;43(3):247–254.CrossRefGoogle ScholarPubMed
Molendijk, ML, Bus, BA, Spinhoven, P, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry. 2011;16(11):1088–1095.CrossRefGoogle ScholarPubMed
Sheehan, DV, Lecrubier, Y, Sheehan, KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33;quiz 34–57.Google ScholarPubMed
Nemeroff, CB, Owens, MJ. Neuropharmacology of paroxetine. Psychopharmacol Bull. 2003;37(suppl 1):8–18.Google ScholarPubMed
Owens, MJ, Krulewicz, S, Simon, JS, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33(13):3201–12.CrossRefGoogle ScholarPubMed
Shavitt, RG, Requena, G, Alonso, P, et al. Quantifying dimensional severity of obsessive–compulsive disorder for neurobiological research. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):206–212.CrossRefGoogle ScholarPubMed
Qin, H, Samuels, JF, Wang, Y, et al. Whole-genome association analysis of treatment response in obsessive–compulsive disorder. Mol Psychiatry. 2016;21(2):270–276.CrossRefGoogle ScholarPubMed
Fullana, MA, Alonso, P, Gratacòs, M, et al. Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive–compulsive disorder. Eur Psychiatry. 2012;27(5):386–390.CrossRefGoogle ScholarPubMed
Timpano, KR, Schmidt, NB, Wheaton, MG, et al. Consideration of the BDNF gene in relation to two phenotypes: hoarding and obesity. J Abnorm Psychol. 2011;120(3):700–707.CrossRefGoogle ScholarPubMed
Katerberg, H, Lochner, C, Cath, DC, et al. The role of the brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD). Am J Med Genet B Neuropsychiatr Genet. 2009;150B(8):1050–1062.CrossRefGoogle Scholar
Yan, T, Wang, L, Kuang, W, et al. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: a systematic review and meta-analysis. Asia Pac Psychiatry. 2014;6(3):241–251.CrossRefGoogle ScholarPubMed
Denys, D, Van Nieuwerburgh, F, Deforce, D, et al. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68(5):747–753.CrossRefGoogle Scholar
Sina, M, Ahmadiani, A, Asadi, S, et al. Association of serotonin receptor 2a haplotypes with obsessive–compulsive disorder and its treatment response in Iranian patients: a genetic and pharmacogenetic study. Neuropsychiatr Dis Treat. 2018;14:1199–1209.CrossRefGoogle ScholarPubMed